Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Summary

This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day treatment with famciclovir (125 mg 12-hourly) in patients with active recurrent genital herpes. This study is not recruiting patients in the United States.

Timeline

Start

2003-01

Primary completion

—

Completion

2006-02

Drugs

Indications